JP Morgan Downgrades Novavax to Underweight, Announces $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph has downgraded Novavax (NASDAQ:NVAX) from Neutral to Underweight and set a price target of $8.
July 30, 2024 | 10:27 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan analyst Eric Joseph downgraded Novavax from Neutral to Underweight and set a price target of $8.
The downgrade from a major financial institution like JP Morgan, along with a significantly lower price target, is likely to negatively impact investor sentiment and the stock price of Novavax in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100